(3aR,7aR)-4-diazo-3,3,7a-trimethyl-2,3a-dihydro-1H-inden-5-one
C12H16N2O — CID 162786862
Data last refreshed: (MolForge compound catalog, from PubChem)
About (3aR,7aR)-4-diazo-3,3,7a-trimethyl-2,3a-dihydro-1H-inden-5-one
(3aR,7aR)-4-diazo-3,3,7a-trimethyl-2,3a-dihydro-1H-inden-5-one (PubChem CID 162786862) has the molecular formula C12H16N2O and a molecular weight of 204.27 g/mol. Its IUPAC name is (3aR,7aR)-4-diazo-3,3,7a-trimethyl-2,3a-dihydro-1H-inden-5-one.
Molecular Properties
| Compound Name | (3aR,7aR)-4-diazo-3,3,7a-trimethyl-2,3a-dihydro-1H-inden-5-one |
|---|---|
| PubChem CID | 162786862 |
| Molecular Formula | C12H16N2O |
| Molecular Weight | 204.27 g/mol |
| Exact Mass | 204.13 |
| IUPAC Name | (3aR,7aR)-4-diazo-3,3,7a-trimethyl-2,3a-dihydro-1H-inden-5-one |
| SMILES | CC1(C)CC[C@]2(C)C=CC(=O)C(=[N+]=[N-])[C@H]12 |
| InChI | InChI=1S/C12H16N2O/c1-11(2)6-7-12(3)5-4-8(15)9(14-13)10(11)12/h4-5,10H,6-7H2,1-3H3/t10-,12+/m1/s1 |
| InChIKey | NOKAOOFXOFUKBC-PWSUYJOCSA-N |
| XLogP | 2.24 |
| TPSA | 53.47 Ų |
| H-Bond Donors | |
| H-Bond Acceptors | 1 |
| Rotatable Bonds | |
| Heavy Atoms | 15 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 204.27 |
| LogP ≤ 5 | 2.24 |
| H-Bond Donors ≤ 5 | 0 |
| H-Bond Acceptors ≤ 10 | 1 |
Computed Properties (RDKit)
| Structural Alerts | {'alert_name': 'azo_A(324)', 'substructure': 'N/A'}, {'alert_name': 'imine_one_A(321)', 'substructure': 'N/A'}, {'alert_name': 'diazo_group', 'substructure': 'N/A'}, {'alert_name': 'imine_1', 'substructure': 'N/A'}, {'alert_name': 'quaternary_nitrogen_3', 'substructure': 'N/A'} |
|---|
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 162786862 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.